Corbus Pharmaceuticals Holdings, Inc. (CRBP) Stock

Corbus Pharmaceuticals Holdings, Inc. (CRBP) is a Healthcare stock trading at $10.40 (as of 2026-08-21), with a market capitalization of $201.15M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Corbus Pharmaceuticals Holdings, Inc. is a biopharmaceutical company developing immune-modulating therapies for immuno-oncology and fibrosis, including lenabasum, an oral CB2-selective activator, and antibody programs (CRB-601 and CRB-602) designed to inhibit TGFß activation in cancer and fibrotic indications. It also advances a CB1 inverse agonist approach for metabolic and fibrotic diseases under development, with related programs supported by a licensing arrangement with Jenrin Discovery, LLC.

Valuation — source: SEC EDGAR (first-party)
Price	$10.40
Market Cap	$201.15M
Price / Book	1.97
FCF Yield	-35.7%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$0.00

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.0

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Cormorant Asset Management, LP ($22.02M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Yuval Cohen
Employees	28
Country	US
IPO Date	2014-10-27

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.